Progress of PARP inhibitors in radiotherapy combined with immunotherapy for NSCLC
10.3760/cma.j.cn113030-20231211-00192
- VernacularTitle:PARP抑制剂在放疗联合免疫治疗非小细胞肺癌的研究进展
- Author:
Yuntao ZHOU
1
;
Ningbo LIU
Author Information
1. 天津医科大学肿瘤医院放疗科，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津 300060
- Keywords:
Radiotherapy;
Immune checkpoint inhibitors;
Carcinoma, non-small-cell lung;
Poly (ADP-ribose) polymerase inhibitors
- From:
Chinese Journal of Radiation Oncology
2024;33(8):760-765
- CountryChina
- Language:Chinese
-
Abstract:
Radiotherapy is the traditional means of treatment for non-small cell lung cancer (NSCLC), and immune checkpoint blockade (ICB) is a major breakthrough in the treatment of NSCLC in recent years. Following the PACIFIC study, several clinical studies of radiotherapy combined with ICB have been carried out successively and achieved better results, but the efficacy of NSCLC still needs to be further improved. Poly ADP-ribose polymerase 1 (PARP1) may be a target to increase the efficacy of radiotherapy combined with ICB. Studies have shown that PARP inhibitors can exert synergistic effects in combination with radiotherapy and ICB. In this paper, we describe the research progress of PARP inhibitors in radiotherapy combined with ICB in the treatment of NSCLC from the mechanism of PARP inhibitors in the treatment of NSCLC, the current status of radiotherapy combined with ICB, and the mechanism and application of PARP inhibitors in radiotherapy combined with ICB in the treatment of NSCLC, in order to assess the potential of the combination therapy in the treatment of NSCLC, and to provide some references for the development of clinical trials in NSCLC.
